Viscoelasticity as a measurement of clot structure in poorly controlled type 2 diabetes patients: Towards a precision and personalized medicine approach

Oncotarget

Volumn 7, Issue 32, 2016, Pages 50895-50907

  Pretorius, Etheresia ^a   Bester, Janette ^a  

^a UNIVERSITY OF PRETORIA   (South Africa)

Author keywords

Coagulation; Pathology Section; Personalized medicine approach; Precision medicine; Type II diabetes; Viscoelasticity

Indexed keywords

HEMOGLOBIN A1C;

ADULT; AGED; ARTICLE; BLOOD CLOTTING; CONTROLLED STUDY; DIABETES CONTROL; DIABETIC PATIENT; DRUG USE; FEMALE; HEMOGLOBIN BLOOD LEVEL; HUMAN; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; NON INSULIN DEPENDENT DIABETES MELLITUS; PERSONALIZED MEDICINE; SCANNING ELECTRON MICROSCOPY; THROMBOELASTOGRAPHY; VERY ELDERLY; VISCOELASTICITY; YOUNG ADULT; ADOLESCENT; BLOOD; PHYSIOLOGY; PROCEDURES;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; BLOOD COAGULATION; DIABETES MELLITUS, TYPE 2; FEMALE; HUMANS; MALE; MIDDLE AGED; PRECISION MEDICINE; THROMBELASTOGRAPHY; YOUNG ADULT;

EID: 84982293373     PISSN: None     EISSN: 19492553     Source Type: Journal    
DOI: 10.18632/oncotarget.10618     Document Type: Article

References (62)

1. Chikowore T, Conradie KR, Towers GW and van Zyl T. Common Variants Associated with Type 2 Diabetes in a Black South African Population of Setswana Descent: African Populations Diverge. Omics. 2015; 19(10):617-626.
2. Camara A, Balde NM, Sobngwi-Tambekou J, Kengne AP, Diallo MM, Tchatchoua AP, Kake A, Sylvie N, Balkau B, Bonnet F and Sobngwi E. Poor glycemic control in type 2 diabetes in the South of the Sahara: the issue of limited access to an HbA1c test. Diabetes Res Clin Pract. 2015; 108(1):187-192.
3. Sharma M, Nazareth I and Petersen I. Trends in incidence, prevalence and prescribing in type 2 diabetes mellitus between 2000 and 2013 in primary care: a retrospective cohort study. BMJ Open. 2016; 6(1):e010210.
4. CDC. (2014). National Diabetes Statistics Report. (http:// www.cdc.gov/diabetes/data/statistics/2014statisticsreport. html) Centers for Disease Control and Prevention). Accessed May 2016.
5. Klein MS and Shearer J. Metabolomics and Type 2 Diabetes: Translating Basic Research into Clinical Application. J Diabetes Res. 2016; 2016:3898502.
6. American-Diabetes-Association. (2016). http://www. diabetes.org/. Accessed May 2016.
7. Pretorius E, Bester J, Vermeulen N, Alummoottil S, Soma P, Buys AV and Kell DB. Poorly controlled type 2 diabetes is accompanied by significant morphological and ultrastructural changes in both erythrocytes and in thrombin-generated fibrin: implications for diagnostics. Cardiovasc Diabetol. 2015; 14:30.
8. Cucuianu M and Coca M. Thrombotic tendency in diabetes mellitus. Revisiting and revising a study initiated 30 years ago. Rom J Intern Med. 2012; 50(2):107-115.
9. Kim HK, Kim JE, Park SH, Kim YI, Nam-Goong IS and Kim ES. High coagulation factor levels and low protein C levels contribute to enhanced thrombin generation in patients with diabetes who do not have macrovascular complications. J Diabetes Complications. 2014; 28(3):365-369.
10. Tousoulis D, Papageorgiou N, Androulakis E, Siasos G, Latsios G, Tentolouris K and Stefanadis C. Diabetes mellitus-associated vascular impairment: novel circulating biomarkers and therapeutic approaches. J Am Coll Cardiol. 2013; 62(8):667-676.
11. Schoenberger SD, Kim SJ, Sheng J, Rezaei KA, Lalezary M and Cherney E. Increased prostaglandin E2 (PGE2) levels in proliferative diabetic retinopathy, and correlation with VEGF and inflammatory cytokines. Invest Ophthalmol Vis Sci. 2012; 53(9):5906-5911.
12. Goldberg RB. Cytokine and cytokine-like inflammation markers, endothelial dysfunction, and imbalanced coagulation in development of diabetes and its complications. J Clin Endocrinol Metab. 2009; 94(9):3171-3182.
13. Wang X, Bao W, Liu J, Ouyang YY, Wang D, Rong S, Xiao X, Shan ZL, Zhang Y, Yao P and Liu LG. Inflammatory markers and risk of type 2 diabetes: a systematic review and meta-analysis. Diabetes Care. 2013; 36(1):166-175.
14. Kampoli AM, Tousoulis D, Briasoulis A, Latsios G, Papageorgiou N and Stefanadis C. Potential pathogenic inflammatory mechanisms of endothelial dysfunction induced by type 2 diabetes mellitus. Curr Pharm Des. 2011; 17(37):4147-4158.
15. Lathief S and Inzucchi SE. Approach to diabetes management in patients with CVD. Trends Cardiovasc Med. 2016; 26(2):165-179.
16. Welty FK, Alfaddagh A and Elajami TK. Targeting inflammation in metabolic syndrome. Transl Res. 2016; 167(1):257-280.
17. Barnett AH. Complementing insulin therapy to achieve glycemic control. Adv Ther. 2013; 30(6):557-576.
18. Buys AV, Van Rooy MJ, Soma P, Van Papendorp D, Lipinski B and Pretorius E. Changes in red blood cell membrane structure in type 2 diabetes: a scanning electron and atomic force microscopy study. Cardiovasc Diabetol. 2013; 12(1):25.
19. Pretorius E, Oberholzer HM, van der Spuy WJ, Swanepoel AC and Soma P. Qualitative scanning electron microscopy analysis of fibrin networks and platelet abnormalities in diabetes. Blood Coagul Fibrinolysis. 2011; 22(6):463-467.
20. Pretorius E, Lipinski B, Bester J, Vermeulen N and Soma P. Albumin stabilizes fibrin fiber ultrastructure in low serum albumin type 2 diabetes. Ultrastruct Pathol. 2013; 37(4):254-257.
21. Bochenek M, Zalewski J, Sadowski J and Undas A. Type 2 diabetes as a modifier of fibrin clot properties in patients with coronary artery disease. J Thromb Thrombolysis. 2013; 35(2):264-270.
22. Dunn EJ, Philippou H, Ariëns RA and Grant PJ. Molecular mechanisms involved in the resistance of fibrin to clot lysis by plasmin in subjects with type 2 diabetes mellitus. Diabetologia. 2006; 49(5):1071-1080.
23. Pretorius E. The adaptability of red blood cells. Cardiovasc Diabetol. 2013; 12:63.
24. Pretorius E and Kell DB. Diagnostic morphology: biophysical indicators for iron-driven inflammatory diseases. Integr Biol. 2014; 6:486-510.
25. Tripodi A, Branchi A, Chantarangkul V, Clerici M, Merati G, Artoni A and Mannucci PM. Hypercoagulability in patients with type 2 diabetes mellitus detected by a thrombin generation assay. J Thromb Thrombolysis. 2011; 31(2):165-172.
26. Ye Y, Perez-Polo JR, Aguilar D and Birnbaum Y. The potential effects of anti-diabetic medications on myocardial ischemia-reperfusion injury. Basic Res Cardiol. 2011; 106(6):925-952.
27. Beijers HJBH, Ferreira I, Spronk HMH, Bravenboer B, Dekker JM, Nijpels G, ten Cate H and Stehouwer CDA. Impaired glucose metabolism and type 2 diabetes are associated with hypercoagulability: potential role of central adiposity and low-grade inflammation-the Hoorn Study. Thromb Res. 2012; 129(5):557-562.
28. Alzahrani SH, Hess K, Price JF, Strachan M, Baxter PD, Cubbon R, Phoenix F, Gamlen T, Ariëns RAS, Grant PJ and Ajjan RA. Gender-specific alterations in fibrin structure function in type 2 diabetes: associations with cardiometabolic and vascular markers. J Clin Endocrinol Metab. 2012; 97(12):E2282-2287.
29. Hess K, Alzahrani SH, Mathai M, Schroeder V, Carter AM, Howell G, Koko T, Strachan MW, Price JF, Smith KA, Grant PJ and Ajjan RA. A novel mechanism for hypofibrinolysis in diabetes: the role of complement C3. Diabetologia. 2012; 55(4):1103-1113.
30. Walus-Miarka M, Wolkow P, Cyganek K, Mirkiewicz-Sieradzka B, Malecki MT and Undas A. Altered fibrin-clot properties are associated with retinopathy in type 2 diabetes mellitus. Diabetes & Metabolism. 2012; 38(5):462-465.
31. Konieczynska M, Fil K, Bazanek M and Undas A. Prolonged duration of type 2 diabetes is associated with increased thrombin generation, prothrombotic fibrin clot phenotype and impaired fibrinolysis. Thromb Haemost. 2014; 111(4):685-693.
32. Pieters M, Covic N, Loots du T, van der Westhuizen FH, van Zyl DG, Rheeder P, Jerling JC and Weisel JW. The effect of glycaemic control on fibrin network structure of type 2 diabetic subjects. Thromb Haemost. 2006; 96(5):623-629.
33. Pieters M, Covic N, van der Westhuizen FH, Nagaswami C, Baras Y, Toit Loots D, Jerling JC, Elgar D, Edmondson KS, van Zyl DG, Rheeder P and Weisel JW. Glycaemic control improves fibrin network characteristics in type 2 diabetes-a purified fibrinogen model. Thromb Haemost. 2008; 99(4):691-700.
34. Hoffman M. Alterations of fibrinogen structure in human disease. Cardiovasc Hematol Agents Med Chem. 2008; 6(3):206-211.
35. Collins FS and Varmus H. A new initiative on precision medicine. N Engl J Med. 2015; 372(9):793-795.
36. Nielsen VG, Kirklin H.K., Hoogendoorn H, Ellis T.C., Holman W.L. Thromboelastographic method to quantify the contribution of factor XIII to coagulation kinetics. Blood Coagul Fibrinolysis. 2007; 18(2):145-150.
37. Nielsen VG. Beyond cell based models of coagulation: analyses of coagulation with clot "lifespan" resistance-time relationships. Thromb Res. 2008; 122(2):145-152.
38. Nielsen VG, Lyerly RT and Gurley WQ. The effect of dilution on plasma coagulation kinetics determined by thrombelastography is dependent on antithrombin activity and mode of activation. Anesthesia and Analgesia. 2004; 99(6):1587-1592.
39. Lipinski B, Pretorius E, Oberholzer HM and van der Spuy WJ. Interaction of fibrin with red blood cells: the role of iron. Ultrastruct Pathol. 2012; 36(2):79-84.
40. Pretorius E. Quantifying changes in fibrin fiber network morphology. Ultrastruct Pathol. 2011; 35(4):150-154.
41. Pretorius E, Briedenhann S, Marx J and Franz RC. Structural changes in the fibrin network of a pretoria family with dysfibrinogenemia: a scanning electron microscopical study. Ultrastruct Pathol. 2006; 30(3):167-176.
42. Nielsen VG, Pretorius E, Bester J, Jacobsen WK, Boyle PK and Reinhard JP. Carbon monoxide and iron modulate plasmatic coagulation in Alzheimer's disease. Curr Neurovasc Res. 2015; 12(1):31-39.
43. Bester J, Soma P, Kell DB and Pretorius E. Viscoelastic and ultrastructural characteristics of whole blood and plasma in Alzheimer-type dementia, and the possible role of bacterial lipopolysaccharides (LPS). Oncotarget Gerontology. 2015; 6(34):35284-35303.
44. Lang E, Qadri SM and Lang F. Killing me softly-suicidal erythrocyte death. Int J Biochem Cell Biol. 2012; 44(8):1236-1243.
45. Lang F and Qadri SM. Mechanisms and significance of eryptosis, the suicidal death of erythrocytes. Blood Purif. 2012; 33(1-3):125-130.
46. Wang Y, Carrim N and Ni H. Fibronectin orchestrates thrombosis and hemostasis. Oncotarget. 2015; 6(23):19350-19351 doi: 10.18632/oncotarget.5097.
47. Bergmeier W and Stefanini L. Platelet signaling-blood's great balancing act. Oncotarget. 2015; 6(24):19922-19923. doi: 10.18632/oncotarget.5122.
48. Grove EL and Gregersen S. Antiplatelet therapy in patients with diabetes mellitus. Curr Vasc Pharmacol. 2012; 10(4):494-505.
49. Salem MA, Adly AA, Ismail EA, Darwish YW and Kamel HA. Platelets microparticles as a link between micro-and macro-angiopathy in young patients with type 1 diabetes. Platelets. 2015:1-7.
50. Carr ME. Diabetes mellitus: a hypercoagulable state. J Diabet Complic. 2001; 15(1):44-54.
51. Banga JD. Coagulation and fibrinolysis in diabetes. Semin Vasc Med. 2002; 2(1):75-86.
52. Thor M, Yu A and Swedenborg J. Markers of inflammation and hypercoagulability in diabetic and nondiabetic patients with lower extremity ischemia. Thromb Res. 2002; 105(5):379-383.
53. Aras R, Sowers JR and Arora R. The proinflammatory and hypercoagulable state of diabetes mellitus. Rev Cardiovasc Med. 2005; 6(2):84-97.
54. Grant PJ. Diabetes mellitus as a prothrombotic condition. J Intern Med. 2007; 262(2):157-172.
55. Cucuianu M, Fekete T, Marcusiu C, Mosler R and Dutu A. Fibrinolysis in diabetes mellitus. Role of overweight and hypertriglyceridemia. Medecine interne. 1984; 22(3):171-177.
56. Yano Y, Kitagawa N, Gabazza EC, Morioka K, Urakawa H, Tanaka T, Katsuki A, Araki-Sasaki R, Hori Y, Nakatani K, Taguchi O, Sumida Y and Adachi Y. Increased plasma thrombin-activatable fibrinolysis inhibitor levels in normotensive type 2 diabetic patients with microalbuminuria. The Journal of clinical endocrinology and metabolism. 2003; 88(2):736-741.
57. Dunn EJ, Ariëns RAS and Grant PJ. The influence of type 2 diabetes on fibrin structure and function. Diabetologia. 2005; 48(6):1198-1206.
58. Alzahrani SH and Ajjan RA. Coagulation and fibrinolysis in diabetes. Diabet Vasc Dis Res. 2010; 7(4):260-273.
59. Li W, Sigley J, Pieters M, Helms CC, Nagaswami C, Weisel JW and Guthold M. Fibrin Fiber Stiffness Is Strongly Affected by Fiber Diameter, but Not by Fibrinogen Glycation. Biophys J. 2016; 110(6):1400-1410.
60. Nielsen VG and Pretorius E. Iron-enhanced coagulation is attenuated by chelation A thrombelastographic and ultrastructural analysis. Blood Coagul Fibrinolysis. 2014; 25(8):845-850.
61. de Villiers S, Swanepoel A, Bester J and Pretorius E. Novel Diagnostic and Monitoring Tools in Stroke: an Individualized Patient-Centered Precision Medicine Approach. J Atheroscler Thromb. 2016; 23(5):493-504.
62. Nielsen VG and Boyer LV. Iron and carbon monoxide attenuate degradation of plasmatic coagulation by Crotalus atrox venom. Blood Coagul Fibrinolysis. 2015.